Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gene Test Could Pinpoint Patients Sensitive to New Type of Cancer Drug

By Institute of Cancer Research | December 22, 2016

Photo: Jan Chlebik for the ICR)

Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.

Scientists found that defects in a gene called ARID1A caused sensitivity to new drugs targeting the DNA repair process within tumour cells.

The new drugs – called ATR inhibitors – are already being tested in early clinical trials, and the new research could help identify those patients who will benefit most.

Scientists at The Institute of Cancer Research, London used molecular screening techniques to find that cancers with mutations in ARID1A were particularly sensitive to ATR inhibitors.

Targeting the tumours

ARID1A is mutated in a wide range of hard-to-treat tumour types, including ovarian cancer and stomach cancer, but until now there has been no way of targeting treatment at tumours with this genetic defect.

The research, which is published in the journal Nature Communications, was funded by Cancer Research UK and Breast Cancer Now.

Scientists at the ICR found that ATR inhibitors stopped cancer cells with ARID1A mutations from growing, both in culture dishes and in mice.

They also found that switching off the ARID1A gene in breast and bowel cancer cells greatly increased their sensitivity to ATR inhibitors.

‘Synthetic lethality’

The researchers found the treatment killed cancer cells with ARID1A mutations through a process called ‘synthetic lethality’.

Cancer cells with ARID1A mutations become particularly reliant on the DNA safeguarding activity of the ATR protein to survive – so they are especially sensitive to drugs that block its effects.

Patients on clinical trials of ATR inhibitors could now start to be tested for ARID1A mutations in their tumours – in order to assess whether those with the genetic defects are particularly likely to benefit.

Dr Chris Lord, Leader of the Gene Function Team at the ICR, said: “Our research has opened up a potential way of personalising treatment for cancer by targeting drugs to those patients who will benefit most.

“We found in cell cultures and in mice that cancers with defective versions of the ARID1A gene are particularly sensitive to a new class of drug called ATR inhibitors.”

“Our research could lead to patients with ARID1A mutant tumours being assessed for whether they respond particularly well to this new class of cancer treatment.”

Step closer to personalised medicine

Dr Justine Alford, Cancer Research UK’s Senior Science Information Officer, said: “By identifying a potential way to exploit a specific genetic vulnerability in cancer this research could point the way to tailoring treatments to each patient, helping to make them kinder and more effective. The next steps will be to better understand the effects of targeting this weakness, and to find out whether this promising strategy will work in people.”

Katie Goates, Senior Research Communications Officer at Breast Cancer Now, said: “This early finding could bring us a step closer to more ‘personalised’ medicine, targeting treatment to exploit weaknesses in patients’ tumours and hopefully improve their chances of survival.

“It’s particularly exciting to see an idea that was initially tested in breast cancer cells be translated into potential benefit for a number of other cancers. We hope these findings now lay the groundwork for clinical trials to investigate the potential of ATR inhibitors as a targeted cancer treatment in the near future.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE